Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | DDIT3 | P35638 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239122 | 0.88 | CYP2D6 (0.32) | CYP2D6KCNH2HRH3ACLYALDH1A1 | |
| SCHEMBL18531901 | 0.84 | EPHX1 (0.36) | ALDH1A1 | |
| SCHEMBL18711984 | 0.83 | HSD11B1 (0.36) | ALDH1A1HSD11B1 | |
| SCHEMBL12385784 | 0.83 | ACLY (0.36) | CYP2D6KCNH2HRH3ACLYDDIT3 | |
| SCHEMBL12201520 | 0.83 | EPHX2 (0.39) | CYP2D6KCNH2HRH3ACLYDDIT3 | |
| SCHEMBL15978962 | 0.80 | MEN1 (0.44) | ALDH1A1HSD11B1 | |
| SCHEMBL26470411 | 0.80 | CA1 (0.42) | CYP2D6KCNH2HRH3ACLYDDIT3 | |
| SCHEMBL1104697 | 0.80 | TP53 (0.46) | CYP2D6KCNH2HRH3ACLYALDH1A1 | |
| SCHEMBL12384633 | 0.79 | EPHX2 (0.44) | CYP2D6KCNH2HRH3ACLYDDIT3 | |
| SCHEMBL12251557 | 0.78 | HSD11B1 (0.44) | ALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210038599-A1 | SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | CYP2D6 4549/4885KCNH2 4476/4885HRH3 1124/4885 |
| US-20210038599-A1 | SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | CYP2D6 4549/4885KCNH2 4476/4885HRH3 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.